Cost-effectiveness analysis of adjuvant docetaxel, doxorubicin, and cyclophosphamide (TAC) for node-positive breast cancer: modeling the downstream effects.
about
Unremarked or Unperformed? Systematic Review on Reporting of Validation Efforts of Health Economic Decision Models in Seasonal Influenza and Early Breast CancerCost effectiveness of TAC versus FAC in adjuvant treatment of node-positive breast cancer.The cost-utility of adjuvant chemotherapy using docetaxel and cyclophosphamide compared with doxorubicin and cyclophosphamide in breast cancer.Cost-utility analyses of drug therapies in breast cancer: a systematic review.Cost-utility analysis of adjuvant therapies for breast cancer in Iran.Granulocyte colony-stimulating factor in secondary prophylaxis for advanced-stage Hodgkin lymphoma treated with ABVD chemotherapy: a cost-effectiveness analysis.Cost-effectiveness analysis of docetaxel versus weekly paclitaxel in adjuvant treatment of regional breast cancer in New Zealand.
P2860
Q26748855-F3BE7706-12CD-4D87-AD86-5EEB92BA1A7EQ33680393-BA77A98B-CCBE-4449-9F2D-BA808D4D306BQ35573019-7EAE2A7A-57D0-4CF3-8982-CD18B30767DBQ36116276-779BF366-8884-4B9F-905B-901E88EDB308Q44401570-CB89C974-DD36-4974-A0EB-9C8015293D69Q50892830-CFD2F6A0-5DCB-46AC-BE64-8DBE393B7AB5Q51732668-D58F8B29-2CF5-4300-A807-3EEDC5A9A396
P2860
Cost-effectiveness analysis of adjuvant docetaxel, doxorubicin, and cyclophosphamide (TAC) for node-positive breast cancer: modeling the downstream effects.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 29 April 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Cost-effectiveness analysis of ...... deling the downstream effects.
@en
Cost-effectiveness analysis of ...... deling the downstream effects.
@nl
type
label
Cost-effectiveness analysis of ...... deling the downstream effects.
@en
Cost-effectiveness analysis of ...... deling the downstream effects.
@nl
prefLabel
Cost-effectiveness analysis of ...... deling the downstream effects.
@en
Cost-effectiveness analysis of ...... deling the downstream effects.
@nl
P2093
P1476
Cost-effectiveness analysis of ...... deling the downstream effects.
@en
P2093
Heather-Jane Au
Kamran Golmohammadi
Konrad Fassbender
Philip Jacobs
Shailendra Verma
Stephen Chia
Tallal Younis
P2888
P304
P356
10.1007/S10549-008-0034-1
P407
P577
2008-04-29T00:00:00Z